In-depth coverage of the UK’s exit from the EU, and what it means to pharma and healthcare.
New cost-capping and delaying measures will further restrict access to new medicines say pharma and patient groups.
March 14, 2017
Significant unmet need still remains in the rare disease market, only around 5% of rare diseases currently have an approved drug treatment. This represents a major opportunity for the pharmaceutical industry. Our webinar will assess the critical factors underpinning success in the rare disease space and provide a view into the future of market access and health technology assessments for orphan medicines – alongside the impact on R&D and clinical trials – in the context of Brexit negotiations.
Experts call for shake-up of EU regulation.
Peers introduce amendment to Brexit bill.
Britain will be in “second or third tier” of drug launches, experts warn.
UK pharma leaders are putting a brave face on Brexit – but the ‘phoney war’ is about to give way to hard-nosed negotiations
But longer-term benefits could include faster reimbursement decisions.
AstraZeneca chief considers two possible scenarios for post-Brexit regulation
Other Japanese firms could scale back UK investment.